Action PRTK PARATEK PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Paratek Pharmaceuticals, Inc.

Actions

PRTK

US6993743029

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract
Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer
Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer
Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. Announces Board Changes
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from NASDAQ Composite Index
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P TMI Index
Gurnet Point Capital Limited and Novo Holdings A/S acquired acquire Paratek Pharmaceuticals, Inc. from a group of shareholders.
Paratek Pharmaceuticals Says Shareholders Approved $462 Million Acquisition by Gurnet Point Capital, Novo Holdings
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PRTK
  4. Actualités Paratek Pharmaceuticals, Inc.
  5. Autres langues